UBS Group’s Biodexa Pharmaceuticals BDRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $1.17K | Buy |
223
+220
| +7,333% | +$2.51K | ﹤0.01% | 10335 |
|
|
2026
Q2 | $73 | Hold |
3
| – | – | ﹤0.01% | 10147 |
|
|
2026
Q1 | $78 | Sell |
3
-50
| -94% | -$2.81K | ﹤0.01% | 10150 |
|
|
2025
Q4 | $4.77K | Sell |
53
-120
| -69% | -$27.3K | ﹤0.01% | 8783 |
|
|
2025
Q3 | $46.1K | Buy |
173
+168
| +3,360% | +$48.2K | ﹤0.01% | 7626 |
|
|
2025
Q2 | $1.72K | Sell |
5
-42
| -89% | -$21.4K | ﹤0.01% | 9575 |
|
|
2025
Q1 | $24.9K | Buy |
47
+29
| +161% | +$40.6K | ﹤0.01% | 8079 |
|
|
2024
Q4 | $28.5K | Sell |
18
-8
| -31% | -$16.7K | ﹤0.01% | 7640 |
|
|
2024
Q3 | $72K | Buy |
26
+25
| +2,500% | +$153K | ﹤0.01% | 6581 |
|
|
2024
Q2 | $8.96K | Buy |
+1
| New | +$10.5K | ﹤0.01% | 7769 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 7679 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 8264 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 8557 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 7163 |
|
|
2023
Q1 | – | Hold |
0
| – | -$123 | – | 9606 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 10375 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 9000 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 9508 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 9272 |
|
|
2021
Q3 | – | Hold |
0
| – | -$16K | – | 9528 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 7562 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 6491 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 8080 |
|
|
2020
Q3 | – | Hold |
0
| – | -$42K | – | 7977 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 6008 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7274 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7815 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7991 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 7522 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7728 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7614 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7394 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7532 |
|
|
2018
Q1 | – | Hold |
0
| – | -$1K | – | 7804 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7693 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7299 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 7664 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6881 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7315 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7116 |
|
|
2016
Q1 | – | Hold |
0
| – | -$12K | – | 7640 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 7161 |
|
Other funds holding BDRX
UBS Group's BDRX Position: Q3 2026 in Review
UBS Group increased its Biodexa Pharmaceuticals (BDRX) stake by 7,333% in Q3 2026, buying an estimated $2.51K and bringing the position to 223 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #10335.
UBS Group first reported a position in BDRX in Q2 2024 and has held it in 10 quarters since. The position peaked at $72K in Q3 2024. 3 funds tracked by Wall St. Rank hold BDRX as of Q3 2026.
- UBS Group held 223 shares of Biodexa Pharmaceuticals worth $1.17K as of Q3 2026.
- UBS Group bought 220 Biodexa Pharmaceuticals shares in Q3 2026, an estimated $2.51K.
- Biodexa Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10335 holding.
- UBS Group first reported a position in Biodexa Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
- UBS Group's Biodexa Pharmaceuticals position peaked at $72K in Q3 2024.
- 3 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.